Elevance Health
ELV

$527.50

2.62%

Market Cap: 122B

About: Elevance Health remains one of the leading health insurers in the U.S., providing medical benefits to 47 million medical members as of December 2023. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states through government-sponsored programs such as Medicaid and Medicare Advantage plans, too.

Employees: 104,900

Financials Hospital & Medical Service Plans

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 26 analysts

0

News positive %

of 18 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

20% more repeat investments, than reductions

Existing positions increased: 642 | Existing positions reduced: 536

8% more capital invested

Capital invested by funds: $97.9B [Q4 2023] → $105B (+$7.36B) [Q1 2024]

6% more funds holding in top 10

Funds holding in top 10: 48 [Q4 2023] → 51 (+3) [Q1 2024]

2% more call options, than puts

Call options by funds: $687M | Put options by funds: $673M

0% less funds holding

Funds holding: 1,616 [Q4 2023] → 1,610 (-6) [Q1 2024]

0.99% less ownership

Funds ownership: 88.41% [Q4 2023] → 87.41% (-0.99%) [Q1 2024]

4% less first-time investments, than exits

New positions opened: 150 | Existing positions closed: 156

See Fund Rankings

Research analyst outlook

26 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$530

0%

upside

Avg. target

$595

13%

upside

High target

$646

22%

upside

26 analyst ratings

25 positive

96%

1 neutral

4%

0 negative

0%

Cantor Fitzgerald Sarah James	14%upside $600	Overweight Reiterated	23 Jul 2024
Wells Fargo Stephen Baxter	12%upside $593	Overweight Maintained	22 Jul 2024
TD Cowen Ryan Langston	12%upside $589	Buy Maintained	19 Jul 2024
Barclays Andrew Mok	16%upside $611	Overweight Maintained	18 Jul 2024
RBC Capital Ben Hendrix	11%upside $585	Outperform Maintained	18 Jul 2024

See Analyst Rankings

Financial journalist opinion

Based on 18 articles about ELV published over the past 30 days

BofA Downgrades Elevance Health On Medicaid Pressure And Lowered Peer Valuations

Wednesday, Elevance Health Inc. ELV reported second-quarter revenues of $43.2 billion, down 0.4% year-over-year, marginally above the consensus of $43.05 billion.

BofA Downgrades Elevance Health On Medicaid Pressure And Lowered Peer Valuations

Elevance Health: Buy A Dividend Growth Machine

Elevance Health, Inc. has shown remarkable dividend growth in the past decade, exceeding revenue and EPS expectations for the first quarter. Elevance's balance sheet remains A-rated, and shares of the stock could be undervalued by 14%. The company is positioned to generate over 30% cumulative total returns through 2026, making it a high-quality investment option.

Elevance Health: Buy A Dividend Growth Machine

Zacks Investment Research

Elevance Health's (ELV) Q2 Earnings Beat on Lower Benefit Expense

Elevance Health's (ELV) Q2 results gain on strong product revenue growth in the Carelon business and a reduced overall expense level. Adjusted earnings are reiterated to be at a minimum of $37.20 per share in 2024.

Elevance Health's (ELV) Q2 Earnings Beat on Lower Benefit Expense

Elevance Health, Inc. (ELV) Q2 2024 Earnings Call Transcript

Elevance Health, Inc. (NYSE:ELV ) Q2 2024 Earnings Call Transcript July 17, 2024 8:30 AM ET Company Participants Steve Tanal - VP of IR Gail Boudreaux - President and CEO Mark Kaye - CFO Felicia Norwood - President, Government Health Benefits Pete Haytaian - President, Carelon Morgan Kendrick - President, Commercial Health Benefits Conference Call Participants A.J. Rice - UBS Nathan Rich - Goldman Sachs Lance Wilkes - Bernstein Kevin Fischbeck - Bank of America Josh Raskin - Nephron Research Lisa Gill - JPMorgan Justin Lake - Wolfe Research Erin Wright - Morgan Stanley Michael Ha - Baird Andrew Mok - Barclays Ryan Langston - Cowen Stephen Baxter - Wells Fargo Scott Fidel - Stephens Sarah James - Cantor Fitzgerald George Hill - Deutsche Bank Whit Mayo - Leerink Partners Dave Windley - Jefferies Ann Hynes - Mizuho Securities Ben Hendrix - RBC Capital Markets Operator Ladies and gentlemen, thank you for standing by, and welcome to the Elevance Health Second Quarter Earnings Conference Call.

Elevance Health, Inc. (ELV) Q2 2024 Earnings Call Transcript

Elevance Stock Slides Despite Earnings Beat as Medicaid Membership Declines

Elevance Health (ELV) topped analyst expectations with its second-quarter results, but shares of the health insurance provider fell in intraday trading Wednesday amid declining Medicaid membership.

Elevance Stock Slides Despite Earnings Beat as Medicaid Membership Declines

Zacks Investment Research

Elevance Health (ELV) Reports Q2 Earnings: What Key Metrics Have to Say

The headline numbers for Elevance Health (ELV) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Elevance Health (ELV) Reports Q2 Earnings: What Key Metrics Have to Say

Elevance Health Beat Street Estimates On Q2 Profit And Revenue, Sticks To Annual Guidance

Elevance Health Inc. ELV reported second-quarter revenues of $43.2 billion, down 0.4% year-over-year, marginally above the consensus of $43.05 billion.

Elevance Health Beat Street Estimates On Q2 Profit And Revenue, Sticks To Annual Guidance

Zacks Investment Research

Elevance Health (ELV) Surpasses Q2 Earnings and Revenue Estimates

Elevance Health (ELV) came out with quarterly earnings of $10.12 per share, beating the Zacks Consensus Estimate of $9.99 per share. This compares to earnings of $9.04 per share a year ago.

Elevance Health (ELV) Surpasses Q2 Earnings and Revenue Estimates

Elevance Health's Profits Hit $2.3 Billion Despite Drop In Medicaid Enrollees

Elevance Health said second quarter profits surpassed $2.3 billion thanks to strong sales of commercial health insurance and growth of healthcare services under the Carelon umbrella that offset the loss of Medicaid health plan members.

Elevance Health's Profits Hit $2.3 Billion Despite Drop In Medicaid Enrollees

Elevance Health Reports Second Quarter 2024 Results

INDIANAPOLIS--(BUSINESS WIRE)---- $ELV #earnings--Elevance Health, Inc. (NYSE: ELV) reported second quarter 2024 results. “Second quarter results reflect the power of our diversified business and thoughtful execution of our strategic initiatives during a dynamic time for our industry, as we remain steadfast in our purpose to improve the health of humanity. We have prudently maintained our full-year outlook and are confident in the earnings power of our Health Benefits and Carelon businesses, which underpin our lo.

Elevance Health Reports Second Quarter 2024 Results

See News Rankings